Blueprint Medicines at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Blueprint Medicines brings 1 presentation to ASH 2026 in New Orleans. Its program centres on systemic mastocytosis. It presents a session on indolent mastocytosis and supports two symposia on diagnosing and treating the disease across its stages.
| Organization | ASH 2026 Attendance |
|---|---|
Blueprint Medicines Cambridge, MA | |
Precision therapy company, now part of Sanofi, known for avapritinib for systemic mastocytosis. | Symposium Fri Dec 11 11:00am–2:00pm Mastering Systemic Mastocytosis: Diagnostic Criteria, Risk Stratification, and Patient-Centered Treatment Across Indolent and Advanced Disease Diagnosing systemic mastocytosis, separating indolent from advanced disease, preventing anaphylaxis, and choosing between symptom control and Kit-targeted drugs. Symposium Fri Dec 11 7:00pm–10:00pm Clinical Turning Points: Decisions That Shape Care Across the Spectrum of Systemic Mastocytosis Recognizing the full symptom burden of non-advanced systemic mastocytosis, judging disease control, and deciding when to escalate to disease-directed therapy. Talk Mon Dec 14 12:15pm–1:15pm |
Find decision makers at Blueprint Medicines
Tell us what you sell and we’ll find the people at Blueprint Medicines most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction